The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levelsTESTA, R; MARCOVINA, S. M.International journal of clinical & laboratory research. 1999, Vol 29, Num 3, pp 128-132, issn 0940-5437Article

The relationship between lipoprotein(a) and the complications of diabetes mellitusKOSCHINSKY, M. L; MARCOVINA, S. M.Acta diabetologica (Print). 2003, Vol 40, Num 2, pp 65-76, issn 0940-5429, 12 p.Article

Expression and characterization of apolipoprotein(a) kringle IV types 1, 2 and 10 in mammalian cellsSANGRAR, W; MARCOVINA, S. M; KOSCHINSKY, M. L et al.Protein engineering (Print). 1994, Vol 7, Num 5, pp 723-731, issn 0269-2139Article

The effect of hormone replacement therapy on lipoprotein(a) levels in postmenopausal womenMARCOVINA, S. M; KOSCHINSKY, M. L.Cardiovascular reviews & reports. 1999, Vol 20, Num 7, pp 387-394, issn 0197-3118Article

Lipoprotein(a) : structural implications for pathophysiologyKOSCHINSKY, M. L; MARCOVINA, S. M.International journal of clinical & laboratory research. 1997, Vol 27, Num 1, pp 14-23, issn 0940-5437Article

Apolipoprotein assays : standardization and quality controlMARCOVINA, S. M; ALBERS, J. J.Scandinavian journal of clinical & laboratory investigation. Supplement. 1990, Vol 50, Num 198, pp 58-65, issn 0085-591X, 8 p.Conference Paper

Die Standardisierung der immunchemisches Bestimmungen von Apolipoprotein A-I und BDATI, F; MARCOVINA, S. M; ALBERS, J. J et al.Behring-Institute-Mitteilungen. 1990, Num 86, pp 116-128, issn 0301-0457Article

Standardization of the immunochemical determination of apolipoproteins A-I and B: a report of the international federation of clinical chemistry meeting on standardization of apolipoprotein A-I and B measurements (basis for future consensus), Vienna, Austria, april 18-19, 1989MARCOVINA, S. M; ALBERS, J. J.Clinical chemistry (Baltimore, Md.). 1989, Vol 35, Num 9, pp 2009-2015, issn 0009-9147Article

International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materialsALBERS, J. J; MARCOVINA, S. M; KENNEDY, H et al.Clinical chemistry (Baltimore, Md.). 1992, Vol 38, Num 5, pp 658-662, issn 0009-9147Article

Standardization of apolipoprotein B and A-I measurementsALBERS, J. J; MARCOVINA, S. M.Clinical chemistry (Baltimore, Md.). 1989, Vol 35, Num 7, pp 1357-1361, issn 0009-9147Article

The unique lipoprotein(a) : properties and immunochemical measurementALBERS, J. J; MARCOVINA, S. M; LODGE, M. S et al.Clinical chemistry (Baltimore, Md.). 1990, Vol 36, Num 12, pp 2019-2026, issn 0009-9147, 8 p.Article

Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and BMARCOVINA, S. M; GAUR, V. P; ALBERS, J. J et al.Clinical chemistry (Baltimore, Md.). 1994, Vol 40, Num 4, pp 574-578, issn 0009-9147Conference Paper

A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City project participantsWILD, S. H; FORTMANN, S. P; MARCOVINA, S. M et al.Arteriosclerosis, thrombosis, and vascular biology. 1997, Vol 17, Num 2, pp 239-245, issn 1079-5642Article

Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel : basis for a standardized isoform nomenclatureMARCOVINA, S. M; HOBBS, H. H; ALBERS, J. J et al.Clinical chemistry (Baltimore, Md.). 1996, Vol 42, Num 3, pp 436-439, issn 0009-9147Article

Human growth hormone increases apo(a) expression in transgenic miceRUIXIAN TAO; ACQUATI, F; MARCOVINA, S. M et al.Arteriosclerosis, thrombosis, and vascular biology. 1999, Vol 19, Num 10, pp 2439-2447, issn 1079-5642Article

Dose-dependent inverse relationship between alcohol consumption and serum Lp(a) levels in black African malesFONTANA, P; MOOSER, V; BOVET, P et al.Arteriosclerosis, thrombosis, and vascular biology. 1999, Vol 19, Num 4, pp 1075-1082, issn 1079-5642Article

Lipoprotein(a) as a risk factor for coronary artery diseaseMARCOVINA, S. M; KOSCHINSKY, M. L.The American journal of cardiology. 1998, Vol 82, Num 12A, pp 57U-66U, issn 0002-9149Conference Paper

Cholesteryl ester transfer protein activity enhances plasma cholesteryl ester formation : Studies in CETP transgenic mice and human genetic CETP deficiencyOLIVEIRA, H. C. F; MA, L; MILNE, R et al.Arteriosclerosis, thrombosis, and vascular biology. 1997, Vol 17, Num 6, pp 1045-1052, issn 1079-5642Article

Lipoprotein(a) is not elevated in non-diabetic microalbuminuric subjects : A longitudinal study of lipoprotein(a) concentrations and apolipoprotein(a) size isoformsYUDKIN, J. S; MARCOVINA, S. M; FOYLE, W.-J et al.International journal of clinical & laboratory research. 1996, Vol 26, Num 1, pp 43-50, issn 0940-5437Article

Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratioALBERS, J. J; TU, A.-Y; PAIGEN, B et al.International journal of clinical & laboratory research. 1996, Vol 26, Num 4, pp 262-267, issn 0940-5437Article

Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)MAHER, V. M. G; BROWN, B. G; MARCOVINA, S. M et al.JAMA, the journal of the American Medical Association. 1995, Vol 274, Num 22, pp 1771-1774, issn 0098-7484Article

Method-dependent variations in the stability of apolipoprotein B in a stabilized liquid reference materialMEI, J. V; POWELL, M. K; HENDERSON, L. O et al.Clinical chemistry (Baltimore, Md.). 1994, Vol 40, Num 5, pp 716-722, issn 0009-9147Article

Lipoprotein(a) as a risk factor for maternal cardiovascular disease mortality in kindreds with familial combined hyperlipidemia or familial hypertriglyceridemiaKIM, H; MARCOVINA, S. M; EDWARDS, K. L et al.Clinical genetics. 2001, Vol 60, Num 3, pp 188-197, issn 0009-9163Article

Interactions between apolipoprotein E and Apolipoprotein(a) in patients with late-onset Alzheimer diseaseMOOSER, V; HELBECQUE, N; MIKLOSSY, J et al.Annals of internal medicine. 2000, Vol 132, Num 7, pp 533-537, issn 0003-4819Article

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitorsPERIARD, D; TELENTI, A; MOOSER, V et al.Circulation (New York, N.Y.). 1999, Vol 100, Num 7, pp 700-705, issn 0009-7322Article